World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
24537
World Ranking
18690
National Ranking
986

Diamant Thaçi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Diamant Thaçi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 491 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Diamant Thaçi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Diamant Thaçi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Diamant Thaçi is affiliated with the University of Lübeck in Germany. Their research primarily spans the fields of Medicine, Immunology, and Microbiology, with a focus on several key subfields including Immunology, Dermatology, Rheumatology, Immunology and Allergy, and Pathology and Forensic Medicine.

The scientist's work covers a range of main topics, notably:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Autoimmune Bullous Skin Diseases
  • Asthma and respiratory diseases
  • Allergic Rhinitis and Sensitization
  • Pharmaceutical studies and practices
  • Urticaria and Related Conditions

Diamant Thaçi has published extensively in a number of scientific journals. Frequent venues include:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of the European Academy of Dermatology and Venereology
  • British Journal of Dermatology
  • Dermatology and Therapy

Key recent papers authored or co-authored by Diamant Thaçi include:

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials, 2021, The Lancet
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine
  • Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial, 2020, Journal of the American Academy of Dermatology
  • Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial, 2022, Journal of the American Academy of Dermatology
  • Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial, 2022, Journal of the American Academy of Dermatology

Among frequent collaborators, Diamant Thaçi has worked significantly with:

  • Richard B. Warren
  • Mark Lebwohl
  • Andrew Blauvelt
  • Melinda Gooderham
  • Bruce Strober

Best Publications

  • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

    Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  • The First European Evidence-Based Consensus on Extra-Intestinal Manifestations in Inflammatory Bowel Disease

    Marcus Harbord;Vito Annese;Stephan R. Vavricka;Matthieu Allez

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

    Philip J. Mease;Dafna D. Gladman;Kim A. Papp;Majed M. Khraishi

  • Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Emma Guttman-Yassky;Henrique D. Teixeira;Eric L. Simpson;Kim A. Papp

  • Psoriasis : a possible risk factor for development of coronary artery calcification

    Ralf J. Ludwig;C. Herzog;A. Rostock;Falk Rudiger Ochsendorf

  • Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    Peter Nash;Bruce Kirkham;Masato Okada;Proton Rahman

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

    Kim Papp;Kenneth Gordon;Diamant Thaçi;Akimichi Morita

  • Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

    Amy S. Paller;Amy S. Paller;Elaine C. Siegfried;Elaine C. Siegfried;Diamant Thaçi;Andreas Wollenberg

  • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

    Phoebe Rich;B. Sigurgeirsson;D. Thaci;J. P. Ortonne

  • Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

    K.A. Papp;M.A. Menter;M. Abe;B. Elewski

  • Psoriasis patients show signs of insulin resistance.

    Sandra Boehncke;Diamant Thaci;Heike Beschmann;Ralf J. Ludwig

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai;Stephen Tyring

  • Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

    K. Papp;D. Thaçi;K. Reich;E. Riedl

  • Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    Emma Guttman-Yassky;Diamant Thaçi;Aileen L. Pangan;H. Chih-ho Hong

Frequent Co-Authors

Matthias Augustin
Matthias Augustin Universität Hamburg
Kim Papp
Kim Papp Probity Medical Research
Kristian Reich
Kristian Reich University of Göttingen
Ulrich Mrowietz
Ulrich Mrowietz Kiel University
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Wolf-Henning Boehncke
Wolf-Henning Boehncke University of Geneva
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Thomas Bieber
Thomas Bieber University of Bonn

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare doesn’t always mean attending traditional, on-campus medical programs. Today, there are many flexible online degrees and certifications that open the door to rewarding paths in medicine and related fields.

For those seeking advanced clinical roles, cheap online dnp programs offer a cost-effective route to leadership positions in nursing. Pharmacists also have new online options, such as the streamlined 3-year online pharmd, which allows students to earn a doctorate in pharmacy in an accelerated timeframe.

Not all healthcare roles require direct patient care. For those interested in the administrative or data side of medicine, you can pursue a bachelor of health information management online. This degree prepares you for managing patient records, health informatics, and regulatory compliance. Additionally, getting a medical coding certification is a quick way to break into a vital, in-demand healthcare career with flexible remote work opportunities.

Exploring these online programs can help you find the best fit for your skills, schedule, and financial situation as you embark on a career in healthcare.

Best Scientists Citing Diamant Thaçi

Trending Scientists

Recently Published Articles